Placeholder Banner

BIO Elects New Board Officers and Members

June 6, 2016


San Francisco, CA (June 6, 2016) – The Biotechnology Innovation Organization (BIO) is pleased to announce the election of two new Board Officers, several new Section Governing Board Chairs, and 21 new members of its Board of Directors, all voted upon at this year’s 2016 BIO International Convention.

Bradford Zakes, Chief Executive Officer, Cerevast Therapeutics, was elected to serve as BIO’s Board Treasurer; and David Meeker, Chief Executive Officer, Genzyme/Sanofi, was elected to serve as Board Secretary.  Ron Cohen, President & CEO, Acorda Therapeutics, was re-elected to another term as Chair.

In addition, BIO announces the election of Alan Shaw, President & CEO, Calysta, as the new Chair of the Industrial & Environmental Section Governing Board; Michael Narachi, President & CEO, Orexigen Therapeutics, as the new Chair of the Emerging Companies Section Governing Board; and Eddie Sullivan, President & CEO, SAB Biotherapeutics, as the new Chair of the Food & Agriculture Section Governing Board.     

“We welcome our new officers, Board leaders, and Board Members, and are looking forward to working with them to create a more favorable policy, legislative, and business development environment for the global biotech industry,” said Jim Greenwood, BIO President & CEO.  “This newly-constituted Board of Directors brings significant industry experience and passion that will serve BIO and its members well.” 

Greenwood also thanked BIO’s departing Board Members, saying, “BIO is deeply appreciative to departing Board Members for their dedication and commitment over the years.”

BIO’s Board also elected a new slate of Executive Committee members for the 2016-2017 term.  They are:

  1. Ron Cohen, President & CEO, Acorda Therapeutics – Board/Health Section Chair  
  2. Bradford Zakes, Chief Executive Officer, Cerevast Therapeutics – Board Treasurer
  3. David Meeker, Chief Executive Officer, Genzyme/Sanofi – Board Secretary
  4. Paul Hastings, President & CEO, OncoMed Pharmaceuticals – Health Section Vice Chair 
  5. Alan Shaw, President & CEO, Calysta – Industrial & Environmental Section (IES) Governing Board Chair
  6. Tjerk de Ruiter, Chief Executive Officer, Corbian – IES Vice Chair
  7. Michael Narachi, President & CEO, Orexigen Therapeutics – Emerging Companies Section (ECS) Governing Board Chair
  8. Eddie Sullivan, President & CEO, SAB Biotherapeutics – Food & Agriculture Section (FAS) Governing Board Chair
  9. Rachel King, Chief Executive Officer, GlycoMimetics – Immediate Past Chair
  10. Alex Azar, President of Lilly USA, Eli Lilly and Company – At-Large
  11. Ian Clark, CEO & Head of North American Commercial Operations, Genentech/Roche – At-Large
  12. Doug Doerfler, President & CEO, MaxCyte – At-Large
  13. Julie Gerberding, Executive Vice President for Strategic Communications, Global Public Policy & Population Health, Merck – At-Large 
  14. Perry Karsen, Chairman & CEO, Jounce Therapeutics – At-Large
  15. John Maraganore, Chief Executive Officer, Alnylam Pharmaceuticals – At-Large
  16. Richard Pops, Chairman & CEO, Alkermes – At-Large
  17. Jay Siegel, Chief Biotechnology Officer & Head of Scientific Strategy & Policy, Johnson & Johnson – At-Large

The full BIO Board of Directors is comprised of the elected Directors serving on each of BIO’s Section Governing Boards.  The newly-elected Board Members from these Sections are:               

Emerging Companies Section Governing Board

  • Julie Smith, President & CEO, Raptor Pharmaceuticals
  • Steven Paul, President & CEO, Voyager Therapeutics  

Food & Agriculture Section Governing Board

  • Brian Barker, General Manager, US Seeds, Dow AgroSciences
  • Rick Van Genderen, Director, Business Management, BASF Plant Science, BASF

Health Section Governing Board

  • Albert Bourla, Group President of Global Innovative Pharma and Global Vaccines, Oncology and Consumer Healthcare Business, Pfizer 
  • Habib Dable, President, U.S. Pharmaceuticals, Bayer
  • Mark Enyedy, President & CEO, ImmunoGen
  • Bill Hinshaw, Executive Vice President and Head, US, Novartis Oncology
  • Joe LaRosa, Senior Vice President, General Counsel and Secretary, Regeneron
  • Jeremy Levin, Chairman of the Board & CEO, Ovid Therapeutics
  • Kiran Mazumdar-Shaw, Chairperson and Managing Director, Biocon Limited
  • David Nicholson, Chief R&D Officer, Allergan
  • James Sapirstein, Chief Executive Officer, ContraVir
  • Julie Smith, President & CEO, Raptor Pharmaceuticals
  • Kathleen Tregoning, Senior Vice President, Corporate Affairs, Biogen
  • Neil Warma, President & CEO, Opexa Therapeutics     

Industrial & Environmental Section Governing Board 

  • Jennifer Holmgren, Chief Executive Officer, LanzaTech
  • John Melo, President & CEO, Amyris


About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.


Upcoming BIO Events 

BIO Latin America Conference
October 26-28, 2016
São Paulo, Brazil

BIO Investor Forum
October 18-19, 2016
San Francisco, CA

Animal Biotech Summit
September 21-23, 2016
Bethesda, MD


Discover More
Most Americans Recognize that Biotech Is ‘Climate Tech’ A new poll from the Biotechnology Innovation Organization (BIO) shows that majorities of Americans agree that biotech plays an important role in addressing climate change and federal…
The White House just announced plans to use Bayh-Dole “march-in rights” to step in and license patent rights of drugs “developed with federal funding” to other manufacturers when the price of the drug is deemed too high. BIO's Chief Advocacy Officer…
Today, the Biotechnology Innovation Organization released a poll that shows voters overwhelmingly support the ORPHAN Cures Act, a recently introduced bill that would incentivize rare disease drug development.   The…